Better Choice Company Signs Binding Letter of Intent to Acquire Choice Specialty Pharmacy, Expanding U.S. Presence
Portfolio Pulse from
Better Choice Company, Inc. (NYSE American: BTTR) has signed a binding Letter of Intent to acquire Choice Specialty Pharmacy Group, enhancing its U.S. specialty pharmacy presence. The acquisition price is based on 6X of the Seller's FY2024 Adjusted EBITDA of approximately $4.68 million, with payment in stock and cash.
March 11, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Choice Company is set to acquire Choice Specialty Pharmacy, which will expand its U.S. specialty pharmacy operations. The acquisition is valued at 6X the Seller's FY2024 Adjusted EBITDA of $4.68 million, paid in stock and cash.
The acquisition of Choice Specialty Pharmacy is a strategic move for Better Choice to enhance its presence in the U.S. specialty pharmacy market. The deal is financially significant, valued at 6X the Seller's FY2024 Adjusted EBITDA, and involves both stock and cash, indicating a substantial investment. This is likely to positively impact BTTR's stock price in the short term as it expands its market reach and capabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100